This study still failed to demonstrate activity of sorafenib in ACC, suggesting that subtherapeutic exposure to VEGFR TKIs is not the only factor driving tumor resistance to this mechanism of action. This evidence concerns the gene KDR and adrenal cortex carcinoma.